Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Shares Outstanding (Weighted Average) (2019 - 2025)

Bioadaptives' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $12.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $12.0 million for Q4 2025, up 46.17% from a year ago — trailing twelve months through Dec 2025 was $12.0 million (up 46.17% YoY), and the annual figure for FY2025 was $12.0 million, up 46.17%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $12.0 million at Bioadaptives, up from $10.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.1 billion in Q3 2024 to a low of $6.0 million in Q4 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $43.7 million (2021), against an average of $235.2 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 553.99% in 2023, then plummeted 99.08% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $33.7 million in 2021, then surged by 214.17% to $106.0 million in 2022, then tumbled by 94.37% to $6.0 million in 2023, then surged by 37.57% to $8.2 million in 2024, then skyrocketed by 46.17% to $12.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $12.0 million, $10.9 million, and $9.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.